
---
title: '中信建投：医药板块反弹符合预期 关注后疫情时代投资主线'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=7267'
author: 证券时报网
comments: false
date: Mon, 28 Feb 2022 08:00:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=7267'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS601066" style="color: #2f67d1;text-decoration: none;" code="601066" target="_blank">中信建投</a>研报认为，经过前期的调整和消化，医药板块高估值的压力得到逐步释放，近期反弹符合预期。站在目前时点，基于对疫情防控政策谨慎乐观的预期，应该将更多的关注点转向“后疫情时代的投资主线”，也就是考虑在新常态下的行业恢复或者基于行业长期主线的投资上。看好：生命科学及上游产业链投资机会：原料药（<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ000739" style="color: #2f67d1;text-decoration: none;" code="000739" target="_blank">普洛药业</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603520" style="color: #2f67d1;text-decoration: none;" code="603520" target="_blank">司太立</a>等）、生命科学（<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688105" style="color: #2f67d1;text-decoration: none;" code="688105" target="_blank">诺唯赞</a>等）、制药产业链上游（<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300171" style="color: #2f67d1;text-decoration: none;" code="300171" target="_blank">东富龙</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300358" style="color: #2f67d1;text-decoration: none;" code="300358" target="_blank">楚天科技</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300813" style="color: #2f67d1;text-decoration: none;" code="300813" target="_blank">泰林生物</a>等）、器械产业链上游（<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688301" style="color: #2f67d1;text-decoration: none;" code="688301" target="_blank">奕瑞科技</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688677" style="color: #2f67d1;text-decoration: none;" code="688677" target="_blank">海泰新光</a>）；以信达生物、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600276" style="color: #2f67d1;text-decoration: none;" code="600276" target="_blank">恒瑞医药</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300760" style="color: #2f67d1;text-decoration: none;" code="300760" target="_blank">迈瑞医疗</a>等为代表的创新药械头部公司的国际化能力；CXO行业：长期看好，建议重点关注国际化能力强的一体化公司。（违法和不良信息举报电话：0755-83514034邮箱：bwb@stcn.com）</p>

                  
</div>
            